Parexel CFO talks earnings, new business

By Melissa Fassbender contact

- Last updated on GMT

The complexity of clinical trials makes converting new business into revenue challenging. (Image: iStock/AndreyPopov)
The complexity of clinical trials makes converting new business into revenue challenging. (Image: iStock/AndreyPopov)

Related tags: New business, Revenue

Parexel has announced its financial results for the third quarter of FY16, which remained strong in spite of the complexities associated with smaller clinical trials.

The company performed well​,” Ingo Bank, Parexel's CFO, told Outsourcing-Pharma.com. “The quarter was one of our best ever for new business wins​.”

As a result of new business, the company’s book-to-bill ratio improved sequentially to 1.33, with gross new business reaching $999m. Additionally, service revenues were $527.1m, up 5.0%, compared to $502m in the prior year’s period.

Revenues meeting our expectations, led by our informatics and consulting businesses, and continued margin improvement drove diluted EPS growth of over 30% year over year​,” said Bank.

However, despite strong new business growth, Bank explained that the company is “seeing a lag in converting new business into revenue​.” 

According to Bank, the reason for this is that most of the company’s clinical trials are small and complex, which results in longer site initiation and start-up times, and challenges with patient accrual. 

We think this prolongation of trials will have reached steady state sometime in Fiscal Year 2017​,” added Bank. “At that point, revenue growth may begin to come more in line with recent backlog growth​.”

The company’s backlog, as of March 31, 2016, was $5.7bn, which is an increase of 9.1% year-over-year.

Our pipeline of new business opportunities to drive future backlog growth remains strong​,” said Bank, who added that to company expects to see continuing growth in biopharma R&D spending and outsourcing penetration. “We believe we are well-positioned​,” he said.

Our goal is to compete effectively with other biopharmaceutical services companies by continuing to build our leadership position in our core businesses and by investing in adjacent areas to serve more of our customers’ needs​.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us

Products

View more

Webinars